New breakthrough may lead to HIV relapse cure

Image
IANS Sydney
Last Updated : Oct 11 2015 | 3:48 PM IST

Scientists are now better able to predict how quickly the HIV virus will return after individuals stop treatment, thanks to the discovery of new immune system biomarkers by researchers at the University of New South Wales (UNSW), Australia, and the University of Oxford.

The development opens up new avenues for understanding why the HIV virus persists in some patients, and remains dormant and undetectable in others.

While existing anti-retroviral therapy (ART) stops the HIV virus from replicating, it does not completely remove the virus. Destroying the hidden reservoirs of the virus remains one of the holy grails of HIV research.

Led by Oxford researcher professor John Frater, the international research team analysed data from a randomised study of patients with primary HIV infection.

They compared the T-cells of 154 patients in Europe, Brazil and Australia who had their ART treatment interrupted after 12 or 48 weeks.

T-cells play a central role in protecting the immune system.

After coming up with a shortlist of 18 immune system biomarkers, researchers discovered that three of them -- PD-1, Tim-3 and Lag-3 -- were statistically significant predictors of when the virus would rebound.

The researchers found that high levels of these biomarkers, attached to 'exhausted' T-cells prior to patients commencing ART, were associated with earlier rebound of the virus following treatment interruption.

"Focusing on the exhaustion markers was an important step as it has given us vital clues as to why some people are able to better control the virus after therapy has been interrupted," said Professor Rodney Phillips from UNSW.

Study co-author Professor Anthony Kelleher from UNSW said understanding the mechanisms that allow HIV to remain in 'remission' is essential if the virus is to be eradicated.

"We want to be able to predict how the virus will behave before we take patients off ART to test drug therapies aimed at eradicating HIV," he said.

The findings were published in the journal Nature Communications.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 11 2015 | 3:36 PM IST

Next Story